Opioid detox for Jupiter — fentanyl-era protocols, buprenorphine done right.

RECO Island is 32 miles south of Jupiter — 45 minutes down I-95 to a small-census, physician-led detox with 24/7 nursing and direct in-house step-down to residential. Buprenorphine induction is COWS-guided and built for the fentanyl era, including low-dose protocols for heavily fentanyl-exposed patients. Every client leaves with naloxone, MAT initiated (or actively refused after counseling), and a same-team transition to the next level of care.

Jupiter sits 32 miles north of RECO Island’s Delray Beach campus — a 45-minute run south on I-95 outside of rush hour. For families in Abacoa, Tequesta, Jupiter Inlet Colony, Admirals Cove, or Jonathan’s Landing, that distance is short enough to keep loved ones close during a detox stay and far enough to place genuine clinical separation between the client and the neighborhoods where opioid use took hold. RECO Island operates a physician-led, small-census opioid detox with direct in-house transition to residential treatment — no waitlist, no third-party handoff, no repeat intake at a different facility mid-stabilization.

Opioid withdrawal in the fentanyl era

The pre-fentanyl detox playbook — heroin and prescription opioids, predictable half-lives, textbook 24-72 hour withdrawal timelines — no longer maps cleanly to the patients arriving in South Florida in 2026. Fentanyl and its analogs now dominate the illicit supply, and their pharmacokinetics are unlike anything the field managed a decade ago. Fentanyl is highly lipophilic and accumulates in adipose tissue, leaching back into circulation for days after last use. Withdrawal emerges on an unpredictable clock, rebounds when clinicians assume it has resolved, and often peaks later than standard heroin timelines predict.

Adulterants complicate the picture further. Xylazine, a veterinary alpha-2 agonist, is now routinely detected alongside fentanyl and produces its own withdrawal syndrome that is refractory to buprenorphine — it requires separate management with clonidine, tizanidine, and dedicated wound care for the necrotic skin lesions xylazine causes. Novel synthetic opioids (nitazenes, brorphine, isotonitazene) appear intermittently in the supply and are not detected by standard 10-panel urine drug screens. Any current opioid detox protocol has to be built around what patients are actually using, not what the DSM edition assumes they are using.

RECO Island’s medical team runs induction and stabilization with those realities built in: extended observation windows before buprenorphine dosing, screening for xylazine exposure, expanded drug testing where indicated, and clinical vigilance for precipitated withdrawal through the first 24-48 hours of admission.

COWS-guided buprenorphine induction

The Clinical Opiate Withdrawal Scale (COWS) is the operational standard for timing induction. Eleven symptom domains — resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, GI upset, tremor, yawning, anxiety, and gooseflesh — are scored at intake and re-scored at defined intervals through the induction window. Buprenorphine dosing begins when the composite score crosses moderate withdrawal, typically 11 or higher, with initial 2-4 mg sublingual doses titrated over the first 24 hours to a clinically effective daily dose of 8-16 mg.

For patients with recent, heavy fentanyl exposure, standard induction thresholds carry precipitated withdrawal risk even at COWS scores of 11-13. Low-dose induction — the Bernese method uses 0.5 mg divided doses over several days while the patient continues limited full-agonist exposure — or transdermal-to-sublingual bridging via a buprenorphine patch may be indicated instead. The alternative, pushing a full induction dose into a fentanyl-loaded patient, drives clients into severe precipitated withdrawal and out the door before stabilization is complete. It is a clinically avoidable outcome.

Comfort medications support the induction window: clonidine 0.1-0.2 mg every 6-8 hours for autonomic hyperactivity, loperamide for diarrhea, ondansetron for nausea, hydroxyzine or gabapentin for anxiety and insomnia, and cyclobenzaprine or methocarbamol for muscle spasm. Nursing checks vitals and re-scores COWS every 4 hours through the acute phase, tapering as symptoms resolve.

Buprenorphine, methadone, or naltrexone — the MAT decision

Post-detox pharmacotherapy for opioid use disorder has three FDA-approved options with strong outcome evidence, and the decision is made with the client during the detox stay rather than punted to the discharge planner. Buprenorphine (Suboxone, Subutex, Sublocade) is a partial mu agonist with a ceiling effect that materially reduces overdose risk, office-based prescribing under DATA 2000, and a monthly extended-release injectable formulation that removes daily adherence pressure. It is the default pathway for most RECO Island opioid detox clients.

Methadone, a full mu agonist, remains the treatment of choice for patients with prolonged high-dose fentanyl use, prior buprenorphine failure, or specific chronic pain co-morbidities — but requires enrollment at a licensed opioid treatment program (OTP) for observed daily dosing, which becomes a coordination question at discharge. Extended-release naltrexone (Vivitrol) is a mu antagonist administered as a monthly intramuscular injection; it requires a documented 7-10 day opioid-free interval before the first dose and is well-suited to clients who have completed a full detox and want a non-agonist pathway, often those with occupational drug-testing constraints.

The choice is driven by clinical picture, prior treatment response, discharge setting, insurance, and client preference. It is not the same conversation for every client and it is not settled by protocol.

Naloxone education and the post-detox safety net

Overdose mortality is highest in the 30 days following detox — opioid tolerance drops during the abstinent period, and any return to use carries elevated risk of respiratory depression at doses that were previously tolerated. This is the single most well-documented risk window in opioid use disorder, and it is addressed directly rather than left to the discharge summary.

Every opioid detox client and one identified family member or support person receives naloxone (Narcan) education, a take-home rescue kit, and hands-on training before discharge. The training covers overdose recognition, rescue breathing, intranasal naloxone administration, repeat dosing intervals for fentanyl-loaded overdoses, and 911 activation under Florida’s Good Samaritan protections. MAT initiation before discharge — buprenorphine dosed and stable at 12-16 mg daily, or Vivitrol scheduled with the induction date confirmed — is the second half of the safety net. The evidence that continued MAT reduces post-detox mortality by 50% or more is why RECO Island does not discharge medication-free unless the client has been counseled and actively refused.

Admission through step-down: what the stay looks like

Admission begins with a full ASAM Criteria assessment across the six dimensions — intoxication and withdrawal potential, biomedical conditions, emotional and cognitive conditions, readiness to change, relapse potential, and recovery environment. Mental health screening runs in parallel: PHQ-9 for depression, GAD-7 for anxiety, PCL-5 for PTSD, ASRS for attention-deficit patterns commonly co-occurring in opioid use disorder, and a full substance use history that captures polysubstance patterns (benzodiazepines, stimulants, alcohol) that alter detox management.

Individual clinical work begins as soon as the client is oriented and comfortable enough to engage — motivational interviewing (MI) through the early acute phase, transitioning to cognitive behavioral therapy (CBT) for relapse prevention, ACT for values-based recovery goals, and, where trauma is a driver of use, EMDR or trauma-focused CBT during the residential phase.

Step-down from detox to residential is internal. The client walks across the same campus to the same treatment team, not into a fresh intake at a different facility. Continuity of medication, provider relationship, and treatment plan is the point of the model.

Insurance, admissions, and the drive from Jupiter

RECO Island is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and most Blue Cross Blue Shield plans. Verification of benefits is completed before admission and covers detox length of stay, residential authorization, and MAT medications on formulary. Out-of-network PPO plans are frequently accepted with a benefits review completed the same day.

The drive from Jupiter is straightforward: I-95 south to Linton Boulevard, then east to the Delray Beach campus — 32 miles, roughly 45 minutes outside of rush hour. Admissions can coordinate ground transportation from Jupiter, Tequesta, and northern Palm Beach County when clinically indicated, and family members are welcomed on campus for scheduled family programming during the residential phase of care.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.